Aptamer Group PLC - Director Fee Shares and Grant of Options
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Director
Grant of Options
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, today announces that it has issued 12,936,511 new ordinary shares as payment for Non-Executive services and, in line with the Company's RNS announcement of
Director
The Company has issued 9,081,246 new ordinary shares to Pathcelerate Limited for Non-Executive services provided by
Further, the Company has issued 3,855,265 shares to
Share option awards
When the Company announced the Placing, Subscription and Retail Offer (the "Fundraise") on
Aptamer has continued to build on its fee-for-service platform over the last three years and the Company now serves 85% of the global top 20 pharma companies. In
The award of new options has been set at a limit of 863,785,988, maintaining dilution at 25% of the share capital as enlarged by the Fundraise and as approved in the general meeting held on
Details of the awards and terms
The following awards have been made:
|
Name |
Position |
Number of shares subject to awards |
|
Dr |
Chief Executive Officer |
325,314,441 |
|
|
Chief Financial Officer |
137,000,019 |
|
Dr |
Chief Scientific Officer |
111,342,428 |
|
Dr |
Non-executive Chairman |
68,717,042 |
|
|
Non-executive Director |
42,794,202 |
|
Staff |
|
156,134,490 |
|
Unallocated pool |
|
22,483,366 |
|
Total |
|
863,785,988 |
The new options are split into the following awards and subject to the conditions outlined in the following tables:
· Award 1 - shall vest immediately following date of grant, with an exercise price of 0.1p.
· Award 2 - shall vest in three equal tranches on the first, second and third anniversaries of the award, with an exercise price equal to 0.6p. The share price must have been above 0.65p per share for at least 30 days prior to vesting.
· Award 3 - exercisable at 0.69p and vesting in eight equal tranches on achieving share price growth expressed as multiples of 0.6p of 1.50x, 1.75x, 2.00x, 2.25x, 2.50x, 2.75x, 3.00x and 3.25x.
Options are subject to clawback provisions in line with governance best practices, including for underperformance or material misstatement.
The number of options granted to each Director is set out by award as follows:
|
Name |
Award 1 |
Award 2 |
Award 3 |
Total |
|
Dr |
94,394,243 |
106,578,553 |
124,341,645 |
325,314,441 |
|
|
39,330,935 |
44,395,038 |
53,274,046 |
137,000,019 |
|
Dr |
31,464,748 |
35,501,191 |
44,376,489 |
111,342,428 |
|
Dr |
15,732,374 |
26,492,334 |
26,492,334 |
68,717,042 |
|
|
12,585,899 |
14,215,672 |
15,992,631 |
42,794,202 |
|
Staff and unallocated pool |
- |
- |
178,617,856 |
178,617,856 |
|
Total |
193,508,199 |
227,182,788 |
443,095,001 |
863,785,988 |
All in-the-money share options would vest in the event that the Company is acquired (or in the event a person or group shall have acquired or entered into a definitive binding agreement to acquire more than 50% of the issued share capital of the Company or assets of the Company or its subsidiaries representing more than 50% of the consolidated earning power of the Company and its subsidiaries taken as a whole).
The award of these share options is conditional on the surrender of shares options that were issued to eligible Directors and Staff in
Admission and Total Voting Rights
An application will be made for the admission of the Directors' fee shares to trading on AIM, which is expected to become effective on or around
Immediately following Admission, the Company will have 3,468,080,461 ordinary shares of
Additional Information
The following disclosures are made in accordance with the requirements of the
NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a)
|
Name
|
Dr |
||||||||||||
|
2 |
Reason for the notification |
|||||||||||||
|
a)
|
Position/status
|
Non-executive Chairman Non-executive Director |
||||||||||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
|
a) |
Name |
Aptamer Group plc |
||||||||||||
|
b) |
LEI |
213800Y4XGH3WJNBE686 |
||||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
||||||||||||
|
|
|
|||||||||||||
|
Identification code |
GB00BNRRP542 |
|||||||||||||
|
|
|
|||||||||||||
|
b)
|
Nature of the transaction |
Grant of share options |
||||||||||||
|
c) |
Price(s) and volume(s) |
|
|
|
|
|||||||||
|
d) |
Aggregated information |
|
||||||||||||
|
|
|
|||||||||||||
|
- Aggregated volume |
12,936,511 |
|||||||||||||
|
- Price |
0.7708p |
|||||||||||||
|
|
|
|||||||||||||
|
e)
|
Date of the transaction |
|
||||||||||||
|
f)
|
Place of the transaction |
Off market |
||||||||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
a)
|
Name
|
Dr Dr Dr |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
2 |
Reason for the notification |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
a)
|
Position/status
|
Chief Executive Officer Chief Financial Officer Chief Scientific Officer Non-executive Chairman Non-executive Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
b)
|
Initial notification /Amendment |
Initial notification |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
a) |
Name |
Aptamer Group plc |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
b) |
LEI |
213800Y4XGH3WJNBE686 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Identification code |
GB00BNRRP542 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
b)
|
Nature of the transaction |
Grant of share options |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
d)
|
Aggregated information |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
- Aggregated volume |
193,508,199, 227,182,788 and 264,477,145 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
- Price |
0.1p each, 0.6p each and 0.69p each |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
e)
|
Date of the transaction |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
f)
|
Place of the transaction |
Off market |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker Andrew Thacker / |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations |
+44 (0) 113 730 3896 |
The information contained within this announcement is deemed to constitute inside information as stipulated under the
About Aptamer Group
Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.
The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.
Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.
The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with upcoming in vivo studies expected to support future partnering and licensing opportunities.
Founded in 2008 and headquartered in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE